Formation Secures Huge Series D For AI Platform Growth

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

Bio Bytes
• Source: Shutterstock

New York-based Formation Bio originally launched in 2016 under the name TrialSpark as a service provider that helped companies more rapidly enroll clinical trials. Its prior investors Sequoia, Thrive, Emerson Collective and Lachy Groom participated in the recent series D round along with new investors, including SV Angel Growth and FPV Ventures. 

More from Deal-Making

More from In Vivo